Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 30:2022:1889628.
doi: 10.1155/2022/1889628. eCollection 2022.

Effects of Tenofovir Combined with Recombinant Human Interferon α-2b on Negative Conversion Rate, Liver Function, Immune Status, and Drug Safety in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis

Hui Zhang  1 , Jianchun Xian  1 , Yang Li  1 , Li Xiao  1 , Lu Wang  2
Affiliations

Effects of Tenofovir Combined with Recombinant Human Interferon α-2b on Negative Conversion Rate, Liver Function, Immune Status, and Drug Safety in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis

Hui Zhang et al. Evid Based Complement Alternat Med. .

Retraction in

Abstract

Objective: To systematically evaluate the clinical value of tenofovir combined with recombinant human interferon α-2b in the treatment of chronic hepatitis B and to provide evidence-based medicine for its popularization and use.

Methods: The randomized controlled trials (RCTs) of tenofovir combined with recombinant human interferon α-2b in the online database of PubMed, EMBASE, ScienceDirect, Cochrane Library, China knowledge Network (CNKI), China VIP database, Wanfang database, and China Biomedical Literature Database (CBM) were searched. The data included in this study were extracted by two independent researchers. After extracting the data of the study, the Cochrane manual 5.1.0 standard was used to evaluate the bias risk of all the literature included in this study. RevMan5.4 statistical software was used to analyze the collected data by meta.

Results: Entecavir combined with recombinant human interferon α-2b can inhibit the activity of HBV polymerase and improve the inflammatory response of the liver. Recombinant human interferon α-2b can regulate immune function by inducing T cell differentiation and maturation and enhancing the production of cytokines. The systematic evaluation showed that entecavir combined with recombinant human interferon α-2b had higher serum HBeAg negative conversion rate, higher drug safety compared with entecavir alone, and improved liver function and immune status.

Conclusion: Tenofovir combined with recombinant human interferon alpha-2b has a high serum HBeAg negative rate and safety profile for the treatment of chronic hepatitis B. The combination treatment can improve liver function and immune status in patients, but more studies with higher methodological quality and longer duration of intervention are needed for further validation.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Forest plot of meta-analysis of the negative conversion rate of HBeAg.
Figure 2
Figure 2
Forest plot of meta-analysis of security.
Figure 3
Figure 3
Forest plot of meta-analysis of liver function score.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Wu Y., Cheng C., Lai W., Qiu Z., Zhang Li. Effect of tenofovir combined with pegylated interferon α-2b injection on serological conversion rate and negative conversion rate of HBeAg in patients with chronic hepatitis B. Advances in Modern Biomedicine . 2021;21(10):1938–1941.
    1. Du J., Wang Y., Li win, Yang R., Zhao W. Effects of pegylated interferon α-2a combined with tenofovir axetil on collagen metabolism, YKL-40, MMP-2 and MMP-9 in patients with chronic hepatitis B. Clinical Medical Research and practice . 2020;5(34):80–82.
    1. Xiao F., Wang M., Zhou L., Yin F., Wang Z. Clinical observation of pegylated interferon α-2b combined with tenofovir in the treatment of HBeAg positive chronic hepatitis B for 48 weeks. Journal of Aerospace Medicine . 2020;31(07):832–833.
    1. Xu Y., Wu P. Efficacy and negative conversion rate of tenofovir combined with polyethylene glycol interferon α 2a in the treatment of chronic hepatitis B [J] Jilin Medicine . 2022;43(02):443–445.
    1. Tang L. S. Y., Covert E., Wilson E., Kottilil S. Chronic hepatitis B infection: a review, JAMA, . 2018;319(17):1802–1813. - PubMed

Publication types

LinkOut - more resources